No Data
No Data
Neurogene to Participate in Upcoming Conferences
Neurogene Insiders Placed Bullish Bets Worth US$1.46m
Stifel Maintains Neurogene(NGNE.US) With Buy Rating, Maintains Target Price $46
Neurogene Highlights Progress in Rett Syndrome Program
William Blair Maintains Neurogene(NGNE.US) With Buy Rating
William Blair Reaffirms Their Buy Rating on Neurogene (NGNE)